Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma

Recruiting now · Phase 2

Conditions studied: Renal Cell Carcinoma

In brief

This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.

Key facts

Study ID

NCT06376669

Run by

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

People needed

20

Starts

2025-02-25

Expected to finish

2030-08-01

Last updated by the study team

2026-04-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Biopsy proven renal cell carcinoma.
• No clinical or radiographic evidence of metastatic disease.
• Not a candidate for surgical treatment or local ablative procedures.
• Subjects are able to undergo either an MRI or administration of contrast agent for CT.

You may not qualify if…

• Prior history of radiation treatment with overlapping fields.
• Patients with proven metastatic disease.
• Female subjects who are pregnant or planning to become pregnant during the treatment.

Where it is running

• Sibley Memorial Hospital — Washington D.C., District of Columbia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.